Kenya has begun rolling out long-acting injectable HIV prevention medication to the public, a significant expansion of the country's prevention toolkit that comes as sexual health workers report alarming increases in sexually transmitted diseases among Generation Z Kenyans who never witnessed the devastating AIDS crisis of previous decades.
The injectable pre-exposure prophylaxis (PrEP), administered twice yearly, offers a more convenient alternative to daily oral pills and could dramatically improve prevention adherence among young adults. But health workers say the program's success depends on addressing a deeper problem: a generation that simply doesn't understand how serious HIV and other STDs can be.
The Generational Knowledge Gap
"Majority Gen Z and almost all born 2000+ are clueless about how devastating AIDS can be to a human body," wrote one Kenyan health advocate on social media, highlighting a public health challenge that numbers alone don't capture. "Y'all have never seen the gory pics that were fed to previous generations when HIV/AIDS was at its peak."
That knowledge gap has consequences. Sexual health workers across Kenya report rising rates of gonorrhea, syphilis, and herpes among young adults who assume that if someone "looks healthy," they're safe. Testing before sex remains rare, and condom use has declined among demographics that came of age after antiretroviral drugs made HIV a manageable chronic condition rather than a death sentence.
Dr. Catherine Muthoni, a sexual health researcher at Kenyatta University, told Nation Media that "we're seeing the unintended consequence of our own success in treating HIV. The fear that drove safe sex practices in the 1990s and 2000s is gone, but we haven't replaced it with comprehensive sexual health education."
The Injectable Solution
The government's injectable PrEP program, available to Kenyans aged 16 and above at subsidized cost, represents the latest phase in the country's HIV prevention evolution. Kenya has long been a regional leader in health innovation—the same mobile technology infrastructure that enabled M-Pesa also powers HIV testing networks and treatment adherence tracking.

